| Glaucoma, Open-Angle

Rocklatan vs Xalatan

Side-by-side clinical, coverage, and cost comparison for glaucoma, open-angle.
Deep comparison between: Rocklatan vs Xalatan with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsXalatan has a higher rate of injection site reactions vs Rocklatan based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xalatan but not Rocklatan, including UnitedHealthcare
Sign up to reveal the full AI analysis
Rocklatan
Xalatan
At A Glance
Ophthalmic
Once daily (evening)
Rho kinase inhibitor / prostaglandin F2alpha analogue
Ophthalmic
Once daily
Prostaglandin F2-alpha analogue
Indications
  • Glaucoma, Open-Angle
  • Ocular Hypertension
  • Glaucoma, Open-Angle
  • Ocular Hypertension
Dosing
Glaucoma, Open-Angle, Ocular Hypertension One drop in the affected eye(s) once daily in the evening; do not exceed once daily. If used with other topical ophthalmic drugs, administer at least 5 minutes apart.
Glaucoma, Open-Angle, Ocular Hypertension One drop in the affected eye(s) once daily in the evening; do not exceed once daily dosing.
Contraindications
—
  • Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product
Adverse Reactions
Most common (>=11%) Conjunctival hyperemia, instillation site pain, corneal verticillata, conjunctival hemorrhage
Postmarketing Epithelial corneal edema in patients with pre-existing corneal stromal edema or ocular procedures affecting corneal endothelial function
Most common (5-15%) Foreign body sensation, punctate keratitis, stinging, conjunctival hyperemia, blurred vision, itching, burning, increased pigmentation of the iris
Serious Iris pigmentation changes, eyelid skin darkening, eyelash changes, intraocular inflammation (iritis/uveitis), macular edema including cystoid macular edema
Postmarketing Dizziness, headache, toxic epidermal necrolysis, keratitis, corneal edema and erosions, trichiasis, iris cyst, conjunctivitis, pseudopemphigoid of the ocular conjunctiva, asthma, dyspnea, nausea, vomiting, pruritis, herpes keratitis, angina, palpitations, chest pain
Pharmacology
Fixed-dose combination of netarsudil (Rho kinase inhibitor) and latanoprost (prostaglandin F2alpha analogue) that reduces elevated intraocular pressure by increasing the outflow of aqueous humor.
Latanoprost is a prostaglandin F2-alpha analogue that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rocklatan
  • Covered on 5 commercial plans
  • PA (5/12) · Step Therapy (6/12) · Qty limit (9/12)
View full coverage details ›
Xalatan
  • Covered on 5 commercial plans
  • PA (0/12) · Step Therapy (0/12) · Qty limit (9/12)
View full coverage details ›
UnitedHealthcare
Rocklatan
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (2/8) · Qty limit (4/8)
View full coverage details ›
Xalatan
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Humana
Rocklatan
  • Covered on 0 commercial plans
  • PA (1/3) · Step Therapy (2/3) · Qty limit (1/3)
View full coverage details ›
Xalatan
  • Covered on 0 commercial plans
  • PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rocklatan.
No savings programs available for Xalatan.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
RocklatanView full Rocklatan profile
XalatanView full Xalatan profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.